stockportfolio.pro
Stocks / CBIO vs CERS
CBIO vs CERS
Crescent Biopharma, Inc. and Cerus Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Crescent Biopharma, Inc. (CBIO) | Cerus Corporation (CERS) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $10.84M | $206.13M |
| Net income (latest FY) | $-153.94M | $-15.63M |
| Revenue growth (5y CAGR) | 1.3% | 12.5% |
| Net margin | -1419.6% | -7.6% |
| Return on equity | -75.8% | -24.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CBIO — free Open CERS — freeFrequently asked questions
Which is bigger, CBIO or CERS?
Crescent Biopharma, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CBIO or CERS?
Over the last five fiscal years, Cerus Corporation grew revenue faster — 12.5%/yr versus 1.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.